zanidatamab + tislelizumab + capecitabine + oxaliplatin

This is a **pharmaceutical combination regimen** consisting of four drugs: - **Zanidatamab**: A bispecific monoclonal antibody targeting two non-overlapping extracellular domains of the HER2 protein, inducing HER2 clustering, internalization, downregulation, growth factor pathway inhibition, and immune effector functions (ADCC, ADCP, CDC)[1][3][4]. - **Tislelizumab**: An anti-PD-1 monoclonal antibody that blocks the interaction of PD-1 with its ligands (PD-L1, PD-L2), leading to T-cell activation and enhanced immune response against tumor cells[1][4]. - **Capecitabine**: An oral fluoropyrimidine prodrug of 5-fluorouracil (5-FU), which inhibits thymidylate synthase, resulting in impaired DNA synthesis and tumor cell death[3]. - **Oxaliplatin**: A platinum-based chemotherapeutic agent that causes DNA crosslinking and subsequent apoptosis in rapidly dividing cells[3]. The regimen is under clinical investigation for first-line treatment of **HER2-positive unresectable, locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (GC/GEJC)**. Early-phase trials show promising antitumor activity, high objective response rates, and manageable safety profiles[1][4].

Other names

CAPOX